4932412H11Rik Activators
Chemical activators of leucine rich repeats and death domain containing 1 (LRDD1) engage in various molecular inhibitions to regulate the activity of this protein. Bisindolylmaleimide I, a specific inhibitor of protein kinase C (PKC), can pave the way for LRDD1 activation by halting the negative feedback loops often mediated by overactive PKC. Similarly, the p38 MAP kinase inhibitor, SB 203580, can promote the activation of LRDD1 by removing inhibitory phosphorylation events within the signaling cascade that typically suppress LRDD1 activity. In the realm of phosphatidylinositol 3-kinases (PI3K) inhibition, both LY294002 and Wortmannin exert a similar effect on LRDD1 activation by preventing the phosphorylation and consequent inactivation of upstream activators of LRDD1, thus allowing for its activation.
Further chemical interventions include the use of MEK inhibitors such as PD98059 and U0126, which block the ERK pathway and, by doing so, lift the suppression on LRDD1 to promote its activation. JNK activity, which can also impart inhibitory effects on proteins that regulate LRDD1, is blocked by SP600125, facilitating the activation of LRDD1. Rapamycin, through its inhibition of mTOR, relieves the negative regulation exerted by the mTORC1 complex on LRDD1. In contrast, MG132 operates by inhibiting the proteasome, thus preventing the degradation of proteins that can positively regulate LRDD1, leading to its activation. Z-VAD-FMK, a pan-caspase inhibitor, ensures the activation of LRDD1 by thwarting the caspase-mediated cleavage of proteins essential for LRDD1 activation. Lastly, the IKK Inhibitor VII and SN-50 target the NF-κB pathway; the former blocks the activity of IKK, while the latter inhibits the nuclear translocation of NF-κB, both of which can result in the activation of alternative signaling pathways that include LRDD1 activation. Each chemical, through its distinct mechanism of inhibition, contributes to the complex regulatory landscape governing the activation of LRDD1.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I, a specific protein kinase C inhibitor, can activate leucine rich repeats and death domain containing 1 by inhibiting PKC, which, when overactive, may suppress downstream proteins like leucine rich repeats and death domain containing 1 through negative feedback loops. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAP kinase inhibitor. By inhibiting p38 MAPK, this compound can remove inhibitory phosphorylation events, leading to the activation of leucine rich repeats and death domain containing 1 as part of the signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that can lead to the activation of leucine rich repeats and death domain containing 1 by preventing PI3K from phosphorylating and inactivating proteins that are upstream activators of leucine rich repeats and death domain containing 1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which in turn blocks the ERK pathway. Inhibition of the ERK pathway can lead to the activation of leucine rich repeats and death domain containing 1 by lifting suppression on the protein exerted by the ERK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, and by blocking JNK activity, this compound can activate leucine rich repeats and death domain containing 1 through relief of JNK-mediated inhibition on proteins that regulate leucine rich repeats and death domain containing 1 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that can result in the activation of leucine rich repeats and death domain containing 1 by preventing MEK from exerting its inhibitory effects on the kinase cascade that controls the activation state of leucine rich repeats and death domain containing 1. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, can activate leucine rich repeats and death domain containing 1 by stopping PI3K from phosphorylating and deactivating proteins that are necessary for the activation of leucine rich repeats and death domain containing 1. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, which is part of the mTORC1 complex that can negatively regulate proteins involved in the activation of leucine rich repeats and death domain containing 1, thus rapamycin can enhance the activation of leucine rich repeats and death domain containing 1. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of ubiquitinated proteins, potentially including those that are involved in the positive regulation of leucine rich repeats and death domain containing 1, resulting in its activation. | ||||||
Z-VAD-FMK | 187389-52-2 | sc-3067 | 500 µg | $75.00 | 256 | |
Z-VAD-FMK is a pan-caspase inhibitor that can activate leucine rich repeats and death domain containing 1 by preventing caspase-mediated cleavage and inactivation of proteins that directly activate leucine rich repeats and death domain containing 1. | ||||||